Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 09:55:32 01/06/2026 pm IST			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	1L 89.98T 83.98T 76.55T 1L 97.36L 1L 10.16L 4L 49.77L 4L 4L 1.6Cr	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	1.13Cr 1.01Cr 93.98L 85.66L 1.62Cr 108.95Cr 1.63Cr 11Cr 4.41Cr 56Cr 4.26Cr 4.16Cr 178.75Cr	EV / Sales 2022	-	EV / Sales 2023	1,12,78,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/25/14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/25/15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/25/01	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/25/30	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/24/16	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/24/18	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/24/15	Top Midday Decliners	MT
15/24/15	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/24/27	Top Midday Decliners	MT
25/24/25	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/24/25	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/23/21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/23/21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/23/21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/23/16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/23/24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Share Price

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news: Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

22/24/22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/24/25	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/24/25	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/24/15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/24/15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		848.64
5 years	0		9,561.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
12/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.42TCr
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	5.74TCr
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	4.76TCr
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	4.43TCr
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	4.25TCr
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	4.07TCr
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	3.1TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	2.85TCr
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	2.43TCr
Average	+989.80%	-0.53%	+1,038.95%	+98.25%	3.91TCr
Weighted average by Cap.	+0.12%	-0.84%	+58.77%	+129.91%

	2022	2023
Net sales	-	2.2 1.96 1.83 1.67 3.14 211.78 3.17 22.11 8.57 108.27 8.27 8.09 347.46
Net income	-7.35Cr -6.53Cr -6.1Cr -5.56Cr -10Cr -706.9Cr -11Cr -74Cr -29Cr -361.38Cr -28Cr -27Cr -1.16TCr	-3.79Cr -3.37Cr -3.14Cr -2.86Cr -5.4Cr -364.17Cr -5.45Cr -38Cr -15Cr -186.17Cr -14Cr -14Cr -597.48Cr
Net Debt	45.89L 40.77L 38.06L 34.69L 65.42L 44Cr 66.03L 4.61Cr 1.78Cr 23Cr 1.72Cr 1.69Cr 72Cr	1.12Cr 99.8L 93.14L 84.9L 1.6Cr 107.98Cr 1.62Cr 11Cr 4.37Cr 55Cr 4.22Cr 4.13Cr 177.15Cr